CAAS Capital Management’s Genmab GMAB Stock Holding History

CAAS Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-350,000	Closed	-$11.2M	–	856
2022 Q3	$11.2M	Buy	+350,000	New	+$12.3M	0.54%	25

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CAAS Capital Management's GMAB Position: Q4 2022 in Review

CAAS Capital Management sold out of Genmab (GMAB) in Q4 2022, closing a stake of 350,000 shares — an estimated $11.2M sold.

CAAS Capital Management first reported a position in GMAB in Q3 2022 and held it in 1 quarter. The position peaked at $11.2M in Q3 2022. 237 funds tracked by Wall St. Rank hold GMAB as of Q4 2022.

CAAS Capital Management reported no remaining Genmab position as of Q4 2022 after selling out during the quarter.
CAAS Capital Management sold 350,000 Genmab shares in Q4 2022, an estimated $11.2M.
CAAS Capital Management first reported a position in Genmab in Q3 2022 and held it in 1 quarter.
CAAS Capital Management's Genmab position peaked at $11.2M in Q3 2022.
237 funds tracked by Wall St. Rank held Genmab as of Q4 2022.

Based on CAAS Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.